# Celecoxib in Treating Patients With Early-Stage Rectal Cancer

> **NCT00608595** · NA · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** celecoxib
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** mass spectrometry
- **PROCEDURE:** biopsy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00608595
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-07
- **Primary completion:** 2004-05
- **Final completion:** 2008-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2013-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608595, "Celecoxib in Treating Patients With Early-Stage Rectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00608595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*